Business

This archive collects stories about businesses — from startups and local enterprises to multinational corporations — taking meaningful action on social, environmental, and economic challenges. These reports highlight moments when commerce and accountability intersect in constructive ways.

Measuring Psilocybin Magic Mushroom Micro Doses in Laboratory for A Scientific Experiment, for article on psilocybin therapy

The world’s first Phase 3 psilocybin clinical trial is about to commence

Psilocybin therapy is making history: Compass Pathways will launch the world’s first Phase 3 trial for treatment-resistant depression by the end of 2022, enrolling nearly 1,000 participants across two pivotal studies. This is the threshold every promising drug must cross to become an approved medicine, and no psychedelic compound has crossed it before. For the roughly 100 million people worldwide whose depression doesn’t respond to standard treatments, the stakes are real — current options are few, often invasive, and inconsistently helpful. A single guided dose, if the evidence holds, could reshape what care looks like. Beyond depression, this moment signals that a long-stigmatized class of medicines is finally being tested with the rigor patients deserve.

Injecting vaccine, for article on India HPV vaccine

Indian company develops country’s first HPV vaccine

CERVAVAC, India’s first homegrown cervical cancer vaccine, is priced at just $2.50 to $5.00 per dose — a fraction of what HPV vaccines have cost in wealthy countries for nearly two decades. Developed by the Serum Institute of India, it protects against the HPV strains responsible for the majority of cervical cancers worldwide, and the company aims to produce around 200 million doses in its first two years. Cervical cancer is almost entirely preventable, yet it still kills hundreds of thousands of women each year, mostly in lower-income countries where vaccines have been priced out of reach. An affordable, locally made option doesn’t just change the math for India — it points toward a future where health tools belong to the people who need them most.

Aerial view of cargo ship, for article on blue whale ship strike

World’s largest shipping line reroutes its ships to avoid hitting blue whales

Blue whales off Sri Lanka finally have a powerful ally in their corner. The world’s largest container shipping company voluntarily rerouted its vessels away from waters where pygmy blue whales live and feed — without any regulatory requirement to do so. Scientists estimate a 15-nautical-mile route adjustment could reduce fatal collisions by up to 95% for this resident population. The hope now is that MSC’s move pressures international maritime authorities to make the change binding for all ships. When industry leaders act ahead of regulation, it shows that targeted, science-based advocacy can protect wildlife at a genuinely global scale.